Rizek’s ground-breaking partnership with G42 Healthcare delivers modern healthcare in a new and innovative way

21

Dubai: Rizek, one of the fastest-growing Abu Dhabi-based start-ups, the first ‘super app’ for on-demand healthcare services in the country, is proud to be partnering with G42 Healthcare, a leading health technology company based in Abu Dhabi, to provide UAE residents with PCR tests. 

Abdallah Abu Sheikh, co-founder and CEO of Rizek, said, “In another milestone of service excellence, our partnership with G42 Healthcare represents a giant step forward for streamlined, patient-centric healthcare; we are proud of what we have been able to achieve as the only app in the Middle East to offer at-home PCR tests. Our pledge of progressive services will always be to our users and society at large as well as to the UAE for what the nation has afforded us in ambition and resolve.”

From the onset of the pandemic, Rizek has been instrumental in providing its customers with the utmost convenient healthcare, extending to at-home PCR tests, of which over 100,000 have been administered through its in-app booking. Simple to use, the process involves a customer placing an order for the required test which will be serviced by Biogenix Labs, G42 Healthcare’s laboratory services company, and results will be sent directly to the customer, making this an extremely convenient service. The partnership with G42 Healthcare further consolidates Rizek’s trustworthiness and reliability as an innovative, fundamental healthcare service whose ambitions match those of the wise leadership and their vision of the future. 

Biogenix Labs has been making significant inroads to ensure the safety of the community, being the 1st COVID-19 accredited lab in the UAE, supporting the local healthcare ecosystem with millions of rapid screening tests, becoming the first laboratory in the UAE to introduce COVID-19 testing by saliva samples, supporting the Back-to-School initiative with more than 50,000 school students and staff tested and leading the assessment of antibody levels in all vaccinated volunteers across UAE.

Ashish Koshy, CEO of G42 Healthcare, commented, “We are committed to developing a world-class, sustainable healthcare sector in the UAE and beyond. Our partnership with Rizek will add a new level of capability and capacity in our quest to make our services accessible to all and bring about a new dimension to one-stop healthcare. Biogenix Labs, with its state-of-the-art technology, has championed transformative healthcare solutions in the UAE since the start of the pandemic with rapid COVID-19 testing for a safe, healthy community. Through the Rizek app, our reach and impact will now multiply as more people get to benefit from our highly accurate and standardised tests from the comfort of their homes or offices with ease.”  

G42 Healthcare has been at the forefront in the battle against COVID-19 in the UAE and MENA region through its world’s first phase III trials for inactivated COVID-19 vaccine, dedication to researching drug therapies, mapping trends in the outbreak including virus mutations, and helping in future-proofing the health of the population, in continuation of its efforts to protect all UAE citizens. 

Rizek is actively working with labs, nurses, and healthcare personnel across the UAE to assist in limiting and stopping the spread of COVID-19. Through this partnership with G42 Healthcare, the company will bring PCR testing to users’ doorsteps, emphasizing their well-being and presenting them with safe and convenient patient care. 

About Rizek:

Founded in 2019 by Abdallah Abu-Sheikh, a seasoned entrepreneur from Amman, Rizek is a super app for on demand services that directly connects users to service professionals from a wide range of industries, thereby enabling better and more efficient relationships between them. Through transforming the way services are rendered, Rizek is strengthening the service sector in the region, with a focus on improving service quality and increasing job opportunities. 

About G42 Healthcare:

G42 Healthcare is a leading health technology company, committed to developing a world-class, sustainable healthcare sector in the UAE and beyond. At the forefront in the battle against COVID-19, G42 Healthcare uses its advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conduct research into new vaccines and drug therapies, and map trends in the outbreak including virus mutations. The company was responsible was conducting the world’s first phase III clinical trial of inactivated vaccines across the Pan Arab region with over 43,000 volunteers participating from over 125 nationalities.